
Telix Japan – Upcoming Events in November
We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021….
Read moreNews & Views
We are pleased to announce Telix’s participation at three major industry events in Japan during November 2021….
Read moreTelix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September…
Read moreTelix presented the IPAX-1 study of TLX101 in glioblastoma at the Congress of Neurological Surgeons Annual…
Read moreTelix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021….
Read moreTelix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut…
Read moreTelix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland)…
Read moreTelix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET)…
Read moreTelix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September…
Read moreTelix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68…
Read moreTelix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy,…
Read more